What is DIHEXA?
DIHEXA is a small synthetic peptide analog belonging to the class of angiotensin IV (AngIV)-derived oligopeptides. It was engineered as a modified, metabolically stabilized derivative of the native AngIV fragment, with N- and C-terminal capping groups that distinguish it from the parent sequence and reduce susceptibility to aminopeptidase and carboxypeptidase cleavage. As a research chemical, it is handled and characterized as a defined small-molecule peptide rather than a formulated product.
Structurally, DIHEXA is categorized as a short capped oligopeptide (an amidated, N-acylated construct) built on an angiotensin IV-derived backbone. This capping architecture is the design feature that differentiates it from linear, unprotected peptides and is central to why it is studied as a distinct chemical entity. It is presented as a lyophilized (freeze-dried) solid, the standard physical form for peptides of this size intended for reconstitution in a laboratory setting.
In the scientific literature, DIHEXA is associated with in-vitro and preclinical neuroscience research, where angiotensin IV-derived compounds have been investigated in connection with the hepatocyte growth factor (HGF) / c-Met signaling system and related cell-biology models. American Peptides supplies DIHEXA strictly as a reference material for such laboratory investigation. No physiological, therapeutic, or performance outcomes are claimed or implied, and the compound is not intended for human or veterinary use, diagnosis, or treatment.
Reconstitution & handling
DIHEXA is provided as a lyophilized solid and must be brought into solution before use in laboratory work. Because it is a relatively hydrophobic capped peptide, aqueous solubility can be limited; researchers commonly prepare a concentrated stock in a compatible organic co-solvent such as dimethyl sulfoxide (DMSO) and then dilute into the intended aqueous buffer or assay medium. Bacteriostatic or sterile water alone may not fully dissolve the material, so a small volume of DMSO is often used as the initial solvent to achieve a clear stock. Solvent selection should always be verified for compatibility with the downstream assay system.
For handling, allow the sealed vial to equilibrate to room temperature before opening to minimize condensation onto the hygroscopic solid. Introduce solvent gently down the vial wall and swirl rather than vortexing aggressively; avoid repeated foaming, which can promote aggregation. Prepared solutions should be clear and free of visible particulates. Because peptides are sensitive to freeze-thaw cycling, dividing reconstituted material into single-use aliquots is a standard practice to preserve integrity.
Storage & stability
In its lyophilized form, DIHEXA is best stored sealed, protected from light and moisture, at −20 °C, where capped peptides of this type maintain stability over extended periods. Once reconstituted, the material is far less stable: solutions should be kept refrigerated at 2–8 °C for short-term use or frozen at −20 °C (or colder) in single-use aliquots for longer storage, and repeated freeze-thaw cycles should be avoided. Minimizing exposure to warmth, light, and atmospheric moisture preserves purity and reduces the risk of hydrolysis or aggregation over time.
How it's tested
Each lot of DIHEXA is analytically characterized to confirm identity and purity, with a Certificate of Analysis (COA) available. Purity is determined by reversed-phase high-performance liquid chromatography (HPLC), establishing the ≥99% specification by quantifying the main peak relative to process-related impurities. Identity is typically corroborated by mass spectrometry (MS), which confirms the expected molecular mass of the peptide. Together, HPLC and MS provide orthogonal verification of composition, and the COA documents the analytical results for the specific lot supplied, supporting traceability in a research setting.